Pulse Biosciences Reports Second Quarter 2020 Financial Results

On August 10, 2020 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, reported financial results for the second quarter ended June 30, 2020 (Press release, Pulse Biosciences, AUG 10, 2020, View Source [SID1234563346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Highlights

Completed the CellFX System GLP (good laboratory practice) preclinical study treatments to generate the data required for the planned 510(k) submission to the U.S. Food and Drug Administration (FDA) for an initial FDA clearance with a general dermatologic indication. This puts the Company on track for a 510(k) submission in the next 60-90 days
Conducted a formal Pre-Submission meeting with the FDA to establish the design for the comparative study required for a subsequent 510(k) submission to expand the indication for use of the CellFX System to include a specific indication for Sebaceous Hyperplasia. The meeting resulted in a general agreement on the study design which allows the Company to move forward with an IDE submission and a potential study start in early Q4, as planned
Submitted the CellFX System technical file to its European notified body in pursuit of the CE mark, the regulatory approval that would authorize the Company to commercialize the CellFX System in the EU. Review is currently underway with expectations for receipt of a CE mark for the CellFX System in Q1 2021
Three clinical studies demonstrating favorable results from the investigational use of NPS technology in Nodular Basal Cell Carcinoma, Sebaceous Hyperplasia and Common Warts, respectively, were presented at the virtual American Society for Laser Medicine and Surgery (ASLMS) annual conference
Strengthened balance sheet with the successful completion of a substantially oversubscribed rights offering, incurring minimal offering costs compared to a traditional public offering, delivering greater net proceeds to the Company. The $30.0 million rights offering generated $29.5 million of net proceeds, not including additional potential gross proceeds of $4.5 million through the exercise of issued warrants
Expanded its Board of Directors with the appointment of Richard van den Broek, serving as a member of the audit and the compensation committees of the Board
"We had a very productive second quarter despite the challenging circumstances persisting as a result of the COVID-19 pandemic. We have remained diligent in our efforts to create the safest work environment possible for our employees and the community and I would like to thank our entire team for their continued efforts and dedication. At the same time, we are pleased that we continue to drive progress towards our top priority of achieving regulatory approvals for the CellFX System," said Darrin Uecker, President and CEO of Pulse Biosciences. "We believe our progress on the clinical and regulatory front combined with continued engagement from the scientific community has positioned us favorably for eventual commercialization in the US, Europe and Canada. Lastly, I would like to thank our shareholders for their participation in the rights offering. Proceeds from this offering will enable us to further progress our development, clinical and commercial objectives."

Financial Update

Cash, cash equivalents and investments totaled $37.8 million as of June 30, 2020, compared to $15.9 million as of March 31, 2020. Excluding the net proceeds of the rights offering received in the three months ended June 30, cash used in the second quarter of 2020 totaled $7.9 million. This compares with $9.5 million used in the first quarter of 2020.

Operating expenses for the three months ended June 30, 2020 were $11.4 million, compared to $11.6 million for the prior year period. Second quarter 2020 operating expenses included stock-based compensation expense of $2.4 million, compared to $2.7 million in the second quarter of 2019. The decrease in operating expenses was primarily driven by reduced research and development costs which were partially offset by increases in general and administrative costs in preparation for commercialization.

Operating expenses for the six months ended June 30, 2020 were $23.3 million, compared to $22.1 million for the prior year period. Stock-based compensation expense for the six months ended June 30, 2020 was $5.0 million, compared to $5.1 million in the prior year period. The increase in operating expenses was primarily driven by the expansion of operational infrastructure including marketing and sales functions.

Net loss for the three months ended June 30, 2020 was ($11.3) million compared to ($11.4) million for the three months ended June 30, 2019. Net loss for the six months ended June 30, 2020 was ($23.2) million compared to ($21.4) million for the six months ended June 30, 2019.

Impact of COVID-19

Our operations in the second quarter of 2020 experienced minimal impacts as a result of the COVID-19 pandemic. Product development and regulatory timelines have not been materially affected at this time but due to the uncertain scope and duration of the pandemic, we cannot reasonably estimate the future impact to our operations and financial results.

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call today, August 10, 2020 beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-855-327-6837 for domestic callers or 1-631-891-4304 for international callers. A live and recorded webcast of the event will be available at View Source

McKesson Canada Names Rebecca McKillican Chief Executive Officer

On August 10, 2020 McKesson Corporation reported the appointment of Rebecca McKillican as Chief Executive Officer (CEO), McKesson Canada effective immediately (Press release, McKesson, AUG 10, 2020, View Source [SID1234563362]). McKillican succeeds Domenic Pilla, who announced his plans to retire from the company in late 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As CEO, McKillican is responsible for leading McKesson’s portfolio of businesses in Canada including pharmaceutical distribution operations, McKesson Canada Specialty Health, McKesson’s network of independent pharmacies comprised of I.D.A., Guardian, Remedy’sRx, The Medicine Shoppe, Uniprix, and Proxim, e-commerce retailer Well.ca, and Rexall Pharmacy Group.

"Rebecca’s deep knowledge of retail will be a tremendous asset to McKesson," said Brian Tyler, CEO, McKesson Corporation. "This, together with her strong financial and operational background, positions her well to drive the company’s strategic growth initiatives in Canada and continue delivering solutions centered on the customer across all our offerings."

McKillican joined McKesson three years ago with the acquisition of Well.ca. As President of Well.ca, she grew the online health and wellness retailer to become recognized as Canada’s Number 1 online retailer. McKillican’s background also includes senior roles at New York City-based Kohlberg, Kravis & Roberts (KKR), and strategy consulting with McKinsey & Company.

"I’m tremendously excited about this opportunity," McKillican said. "McKesson Canada is uniquely positioned to drive meaningful value across the healthcare ecosystem while improving access to affordable healthcare. I’m honored to be in a position to lead our dynamic, values driven team in Canada dedicated to operational excellence, working with integrity and accountability and meeting our customers’ needs."

McKillican earned her MBA at the Harvard Business School where she was a Baker Scholar. She also holds an HBA, and a B.ESc in software engineering from Western University. Rebecca is a board member of the National Bank of Canada, and, in 2018, Rebecca was named one of Canada’s Top 40 Under 40.

"I would also like to express my sincere gratitude to Domenic for his many contributions to our company," said Tyler. "Having served almost two decades with McKesson, Domenic has been a visionary leader and a driving force in building and executing a growth strategy for the Canadian business that delivers better patient care. Working collaboratively with governments and industry partners, Domenic’s work has cemented McKesson’s lasting impact on health care in Canada. His legacy is marked by the team of high-performing leaders he’s helped recruit and develop; they share our commitment to improving care in every setting."

VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update

On August 10, 2020 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") reported it will host a conference call on Friday, August 14, at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020, in addition to providing a business update (Press release, VolitionRX, AUG 10, 2020, View Source [SID1234563378]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: VolitionRx Limited Second Quarter 2020 Earnings and Business Update Conference Call
Date: Friday, August 14, 2020
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13707978

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition’s activities, including details of new and ongoing clinical trials, important events which have taken place in the second quarter of 2020, and milestones for 2020 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at View Source In addition, a telephone replay of the call will be available until August 28, 2020. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13707978.

Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021

On August 10, 2020 The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) reported that has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454). It is divided into up to 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each and a total nominal value of up to EUR 7,914,450 (Press release, Biofrontera, AUG 10, 2020, View Source [SID1234568548]). The shareholders or holders of subscription rights were invited by an announcement in the Federal Gazette (Bundesanzeiger) of 29 July 2020 to exercise their subscription rights to the Bonds during normal business hours in the period from 30 July 2020 up to 13 August 2020 (included) to avoid exclusion. It was also provided that the subscription price would be published in the Federal Gazette (Bundesanzeiger) and via an electronic information medium no later than three days before the end of the subscription period.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The subscription price for each of the Bonds was set at

100 % of their nominal value of EUR 3,00.

Thus, the cash payment for each bond subscribed is EUR 3.00.

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

On August 10, 2020 BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, reported that it will be announcing its results for the second quarter 2020 on Tuesday 18 August 2020 (Press release, BerGenBio, AUG 10, 2020, View Source [SID1234563253]). A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.

The second quarter report and presentation will be available on the Company’s website in the Investors/Financial Reports section from 7:00 am CET the same day.